" class="no-js "lang="en-US"> Neutron Therapeutics Announces Successful Neutron Beam
Sunday, May 19, 2024

Neutron Therapeutics Announces Successful Generation of a Neutron Beam for BNCT at Shonan Kamakura General Hospital in Japan

Neutron Therapeutics (NT), a targeted radiation oncology therapy company developing a comprehensive clinical solution for Boron Neutron Capture Therapy (BNCT), today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan.

“We are extremely pleased to announce this exciting milestone in our first installation of a nuBeam® system in the Asia Pacific region,” said Elizabeth Reczek, PhD, CEO of Neutron. “Japan has been at the forefront of the modern, accelerator-based era of BNCT therapy and is the world leader in clinical BNCT research. We are excited to continue this tradition of innovation through our collaboration with SKGH and are proud to offer the only system that conforms to IAEA recommendations for a neutron beam for BNCT.”

BNCT targets cancer at the cellular level by combining a tumor-targeted boron carrier drug with a neutron beam to generate DNA-damaging ionizing radiation within the tumor cell itself, while sparing surrounding normal tissues. With the potential to treat both primary tumors and local metastases in a highly targeted manner with as few as one to two treatments, BNCT represents a disruptive advance in radiation therapy for solid tumors and an exciting new tool in the oncologist’s arsenal. Neutron Therapeutics’ nuBeam® system produces the highest neutron flux available, leading to substantially shorter treatment times and improved patient experience.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more